Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups.

Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E.

Thrombosis. 2013;2013:640723. doi: 10.1155/2013/640723. Epub 2013 Dec 22. Review.

2.

Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients.

Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E.

Br J Clin Pharmacol. 2016 Sep;82(3):633-44. doi: 10.1111/bcp.13005. Epub 2016 Jun 17. Review.

3.

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.

Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY.

BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.

4.

Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.

Adeboyeje G, Sylwestrzak G, Barron JJ, White J, Rosenberg A, Abarca J, Crawford G, Redberg R.

J Manag Care Spec Pharm. 2017 Sep;23(9):968-978. doi: 10.18553/jmcp.2017.23.9.968.

5.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
6.

Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.

Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M.

J Med Econ. 2015 Jun;18(6):399-409. doi: 10.3111/13696998.2015.1007210. Epub 2015 Feb 9.

PMID:
25586203
7.

Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.

Kohsaka S, Murata T, Izumi N, Katada J, Wang F, Terayama Y.

Curr Med Res Opin. 2017 Nov;33(11):1955-1963. doi: 10.1080/03007995.2017.1374935. Epub 2017 Sep 12.

PMID:
28857611
8.

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.

Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M.

Thromb Haemost. 2016 Oct 28;116(5):975-986. Epub 2016 Aug 19.

PMID:
27538358
9.

Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation – meta-analysis.

Senoo K, Lau YC, Dzeshka M, Lane D, Okumura K, Lip GY.

Circ J. 2015;79(2):339-45. doi: 10.1253/circj.CJ-14-1042. Epub 2014 Dec 11. Review.

10.

Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation.

Baker WL, Phung OJ.

Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):711-9. Epub 2012 Aug 21. Review.

11.

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.

Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.

12.

Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.

Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Køber L, Gislason GH, Torp-Pedersen C, Fosbøl EL.

Europace. 2015 Feb;17(2):187-93. doi: 10.1093/europace/euu225. Epub 2014 Sep 18.

PMID:
25236181
13.

Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.

Verdecchia P, Angeli F, Lip GY, Reboldi G.

PLoS One. 2014 Jun 23;9(6):e100478. doi: 10.1371/journal.pone.0100478. eCollection 2014.

14.

Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.

Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S.

Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084. Epub 2015 Nov 17.

PMID:
26655548
15.

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.

Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.

J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.

PMID:
24831811
16.

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, Kansal AR.

Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.

17.

Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.

Kumana CR, Cheung BM, Siu DC, Tse HF, Lauder IJ.

Cardiovasc Ther. 2016 Apr;34(2):100-6. doi: 10.1111/1755-5922.12173. Review.

PMID:
26727005
18.

Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.

Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH.

J Med Econ. 2014 Nov;17(11):771-81. doi: 10.3111/13696998.2014.953682. Epub 2014 Aug 26.

PMID:
25133458
19.

An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.

Deitelzweig S, Bruno A, Trocio J, Tate N, Gupta K, Lin J, Lingohr-Smith M.

Curr Med Res Opin. 2016;32(3):573-82. doi: 10.1185/03007995.2015.1131676. Epub 2016 Jan 1.

PMID:
26652179
20.

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.

Lip GY, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, Bruno A, Phatak H.

Int J Clin Pract. 2016 Sep;70(9):752-63. doi: 10.1111/ijcp.12863. Epub 2016 Aug 23.

Supplemental Content

Support Center